Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06065098 · ClinicalTrials.gov registry record · NA

Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health

A NA study of Hypertension and Diabetes, sponsored by Tulane University.

Recruiting
Registry status
NA
Development phase
806
Enrollment target
1
Study location

NCT06065098: Recruiting NA study of Hypertension and Diabetes, sponsored by Tulane University.

NCT06065098 is a NA study of Hypertension and Diabetes that is actively recruiting participants, run by Tulane University. The registered enrollment target is 806 participants, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06065098, a NA study of Hypertension and Diabetes, is actively recruiting participants, sponsored by Tulane University.

RECRUITING
Registry status
NA
Development phase
806 participants
Enrollment target
1
Study location

Study Summary

Cardiovascular disease (CVD) is the leading cause of death in the US general population. Although CVD mortality rates declined for both Black and White populations during the past two decades, they are still higher in Black adults than White adults. There are also persistent disparities in CVD risk factors with higher prevalence of obesity, hypertension, and diabetes in Black compared to White populations. In addition, CVD and risk factors are more prevalent in the residents of Louisiana compared to the US general population. The Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health (CHERISH) study will use a church-based community health worker (CHW)-led multifaceted intervention to address racial inequities in CVD risk factors in predominantly Black communities in New Orleans, Louisiana. The primary aim of the CHERISH study is to compare the impact of two implementation strategies - a CHW-led multifaceted strategy and a group-based education strategy - for delivering interventions recommended by the 2019 American College of Cardiology (ACC)/American Heart Association (AHA) Guideline on the Primary Prevention of Cardiovascular Disease on implementation and clinical effectiveness outcomes in predominantly Black church community members over 18 months.

Primary Outcome

The ACC/AHA ASCVD risk score will be calculated using the pooled population cohort equation based on age (years), total cholesterol (mg/dL), high-density lipoprotein (HDL)-cholesterol (mg/dL), antihypertensive medication use, systolic BP (mmHg), current smoking status, and diabetes status. The risk score ranges from 0% to 100%.

Interventions

  • BEHAVIORAL Evidence-based interventions recommended by the 2019 ACC/AHA Guideline on the Primary Prevention of CVD

Study Locations (1)

Louisiana

  • Tulane University - New Orleans

Trial Details

FieldValue
Enrollment Target 806 participants
Start Date 2023-09-28
Est. Completion 2027-08-31
Phase NA
Tulane University

73 total trials

What NCT06065098 shows while recruiting

NCT06065098 is an interventional study that assigns participants to a tested intervention. The registered 806 participants enrollment target is mid-sized for trials with a published cap, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (77% lower).

The record links to 4 conditions, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Evidence-based interventions recommended by the 2019 ACC/AHA Guideline on the Primary Prevention of CVD is the first listed.

NCT06065098 reports a single indexed study location in Louisiana.

Frequently Asked Questions

What is clinical trial NCT06065098 about?

NCT06065098 is a clinical study titled "Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health". Cardiovascular disease (CVD) is the leading cause of death in the US general population. Although CVD mortality rates declined for both Black and White populations during the past two decades, they are still higher in Black adults than White adults. There are also persistent disparities in CVD risk ...

What is the current status of trial NCT06065098?

This trial is currently recruiting. It is a NA study. The enrollment target is 806 participants. The study started on 2023-09-28. Estimated completion is 2027-08-31.

What conditions does trial NCT06065098 study?

This clinical trial studies the following conditions: Hypertension, Diabetes, Cardiovascular Diseases, Hypercholesterolemia.

What interventions are being tested in trial NCT06065098?

The interventions under investigation include: Evidence-based interventions recommended by the 2019 ACC/AHA Guideline on the Primary Prevention of CVD (BEHAVIORAL).

Who is sponsoring clinical trial NCT06065098?

This trial is sponsored by Tulane University, which has 73 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06065098 being conducted?

This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06065098's enrollment target sits among peer trials

806 87th of 470 higher than 384 of 470 other Hypertension trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04613596 · 806 participants · Phase 2

    Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  • NCT06529094 · 808 participants · NA

    Implementing a Decision Support Tool to Prevent Community-Acquired Pressure Injury in Spinal Cord Injury (SCI) in the Spinal Cord Injury Clinic

  • NCT04423211 · 804 participants · Phase 3

    Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

  • NCT06522022 · 804 participants · NA

    PTSD Screening in Pregnant Black Women

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06065098, the US trial registry maintained by the National Library of Medicine. NCT06065098 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.